Leverage Your EDC Solution to Mitigate Risk in Clinical Research
-
Upload
datatrak-international-inc -
Category
Healthcare
-
view
163 -
download
0
Transcript of Leverage Your EDC Solution to Mitigate Risk in Clinical Research
![Page 1: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/1.jpg)
Leveraging Your EDC Application to
Mitigate Risk in Clinical Trials
March 25, 2015
![Page 2: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/2.jpg)
Confidential –
Your Speaker
► Bill Gluck, Ph.D.
• Dr. Gluck has over 30 years of expertise in clinical research, with experience in sponsors, CROs, and with DATATRAK in a variety of roles. Dr. Gluck is also the Program Director for the Clinical Trials Research and Medical Product Safety/Pharmacoviligance programs at Durham Technical Community College. Dr. Gluck earned his Bachelor of Science Degree at the University of Scranton and Master and Ph.D. degrees from North Dakota State University.
2
![Page 3: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/3.jpg)
Confidential –
Our Discussion Topics
• Definition and Perception of ‘Risk’
• Risk-Based Quality Management
• How Can We Mitigate Our Risk Profile
– Approaches to Reducing Risk
– Review, Report, Communicate
– Leveraging Technological Tools
• Summary
![Page 4: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/4.jpg)
Confidential –
Every Clinical Trial Has Inherent Risk and
Every Risk Has a Tolerance Limit
4
![Page 5: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/5.jpg)
Confidential –
Risk
5
Risk is an uncertain event
or condition that, if it
occurs, has an effect on at
least one objective.
![Page 6: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/6.jpg)
Confidential –
Mitigating Risk
6
Taking steps to reduce adverse effects.
![Page 7: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/7.jpg)
Confidential –
Tolerance
7
There is no way a sponsor
can eliminate all risks of
doing clinical trials so
defining the amount and
identifying the type of risk
that a sponsor is willing to
accept helps them evaluate
where resources should
allocated to minimize the
most significant risks.
![Page 8: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/8.jpg)
Confidential –
Perception of Risk
Role and Responsibilities
– Sponsor
– Investigator
– IRB/Ethics Committee Member
– Quality Representative
– Regulator
![Page 9: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/9.jpg)
Confidential –
Risk-Based Quality Management
• Start with Quality – End with Quality
– A systematic process to identify, assess, control,
communicate, and review risks associated with the trial
throughout the life of the trial
![Page 10: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/10.jpg)
Confidential –
One
Approach To
Risk
Mitigation
Identify & Assess
Control
Review & Communicate
10
![Page 11: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/11.jpg)
Confidential –
Identify and Assess Risk
• Privacy Protection of Study Participants
• Patient/Subject Safety
• Quality/Reliability of Study Data
![Page 12: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/12.jpg)
Confidential –
Controlling Risk
• What decisions can be made to reduce and/or
accept risk?
• Where can we mitigate risk?
• How can we accomplish this?
![Page 13: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/13.jpg)
Confidential –
Review and Communication
• Document your process
• Communicate the process
• Review results
• Incorporate new information
• Update and revise your plan as needed
![Page 14: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/14.jpg)
Confidential –
Develop and Implement A Plan
• Building on the answers
– Develop a plan
– Implement action for high risk
– Understand there may be implications with low risk
![Page 15: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/15.jpg)
Confidential –
![Page 16: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/16.jpg)
Confidential –
How Do We Do This?
• Separate prioritization from risk mitigation
• Address each stage of the trial
• Stratify/Customize the plan
![Page 17: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/17.jpg)
Confidential –
Setting Boundaries – Early and Often
• Trial Data
• Monitor Protocol Compliance/Deviations
• Establish Qualification Standards/Specifications
• Define Metrics to Allow Oversight
– Data Collection, Retrieval, and Reporting
– RBM
– Quality Measures
![Page 18: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/18.jpg)
Confidential –
A Sample Template
Header Categories
Risk Area/Category
Potential Risk Assessed
Risk Examples/List study specific issues
Include in Monitoring Plan (Yes/No)
Tolerance Threshold
Mitigation Strategies/Tools to be Used
18
![Page 19: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/19.jpg)
Confidential –
Sample Template Header
19
Risk Assessment
Worksheet
Risk Area/Category Potential Risk Assessed Risk Examples (list study specific
issues)
Include in
Monitoring Plan
(Yes/No) Tolerance Threshhold Mitigation Strategy/Tools to be
Used
![Page 20: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/20.jpg)
Confidential – 20
Study Conduct Quality Management System-Sponsor
Level
Is there a sponsor level QMS in place,
at the CRO/support company level, at
the site level?
Required Regulatory Reporting
Does the sponsor have the
infrastructure to support the required
regulatory reporting needed? Does the
supporting organization have the
infrastructure? Does the site have a
QMS or the essential quality controls in
place?
Specific Study Activities
Informed consent process, enforcement
of INC/EXC, handling protocol
deviations/violations, stopping rules,
SAE handling, dose modifications, etc.
Investigational Product
Is there investigational product in place
to conduct the study, is there a re-
supply process, is the supply chain
establsied, are there regulatory risks for
international studies/transport/storage
of the investigational product?
Safety Concerns
Study participant protection and well-
being processes/procedures in place,
safety monitoring, know adverse
evetns/reactions, process for
documetnation and reporting of
unexpected events and SAE's
Study specific tasks
Endpoints, complexity of the study,
stage of the study, number of potential
study participants and geographic
availability
![Page 21: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/21.jpg)
Confidential –
Leverage Technological Tools – Focus on EDC
► CTMS Applications
► EDC Application
• Platform – Trial-by-Trial Reporting Tools
• Platform – Cross Study Managers/Filters/Reporting Tools
• Performance/Quality Tools
► Safety Application
21
![Page 22: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/22.jpg)
Confidential –
Reporting Quality – Leverage Technology
Critical in Today’s Trials
• Trial Data
• Monitor Protocol Compliance/Deviations
• Establish Qualification Standards/Specifications
• Define Metrics to Allow Oversight
– RBM
• Frequency
• SDV
– Data Collection, Retrieval, and Reporting
– Performance/Quality Measures
![Page 23: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/23.jpg)
Confidential –
Summary
• Risk based approach starts in planning the program
not the study
• Know, Understand, and Use Available Tools
• Adapt protocol-by-protocol throughout the program
– Learn as you go
– Adapt as you go
– Improve as you go
• Communicate, communicate, communicate
– Allow for sponsor and regulatory interactions
![Page 24: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/24.jpg)
Confidential –
Questions
24
![Page 25: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/25.jpg)
Confidential –
Contact Information
► Bill Gluck, Ph.D.
► General Questions about DATATRAK
► Find Us Online
• www.DATATRAK.com
• http://www.slideshare.net/DATATRAK
• @DATATRAKinc on Twitter
• https://www.linkedin.com/company/datatrak-international
25
![Page 26: Leverage Your EDC Solution to Mitigate Risk in Clinical Research](https://reader030.fdocuments.us/reader030/viewer/2022032616/55a680041a28ab5a6f8b48ce/html5/thumbnails/26.jpg)
from Concept to Cure
with DATATRAK ONE
DATATRAK International Chicago, Illinois
Cleveland, Ohio
Bryan, Texas
Cary, North Carolina
United Kingdom
888.677.DATA (3282) Toll Free
www.datatrak.com
®
®